Isabel Smith Zubiaga-rekin lankidetzan egindako argitalpenak (9)

2020

  1. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma

    PLoS ONE, Vol. 15, Núm. 3

2015

  1. Comparison of the transcriptional profiles of melanocytes from dark and light skinned individuals under basal conditions and following ultraviolet-B irradiation

    PLoS ONE, Vol. 10, Núm. 8

2014

  1. The Interplay between natural selection and susceptibility to melanoma on allele 374F of SLC45A2 gene in a south European population

    PLoS ONE, Vol. 9, Núm. 8

2010

  1. The diversity profile of TP53 is influenced by positive selection on the immediately upstream locus WDR79

    Human Heredity, Vol. 69, Núm. 1, pp. 34-44

2008

  1. Complex signatures of selection for the melanogenic loci TYR, TYRP1 and DCT in humans

    BMC Evolutionary Biology, Vol. 8, Núm. 1

1997

  1. Serum-soluble IL-2 Receptor and IL-6 levels in patients with melanoma

    Oncology (Switzerland), Vol. 54, Núm. 5, pp. 400-406

1996

  1. Expression of IL-2 receptor beta-chain in B16 melanoma cells.

    The International journal of developmental biology, Vol. Suppl 1

  2. Serum interleukin-6 levels in patients with melanoma.

    The International journal of developmental biology, Vol. Suppl 1

1994

  1. Enhancement of ia antigen expression and nonproliferating cells correlates with metastatic capacity

    Pathobiology, Vol. 62, Núm. 4, pp. 186-193